Navigation Links
Viragen International to Reverse Split Its Common Stock

- 1 for 40 Split Effective at Close of Business Today

- VGNI Stock Symbol to Change to VRGE

PLANTATION, Fla., Sept. 4 /PRNewswire-FirstCall/ -- Viragen International, Inc. (OTC Bulletin Board: VGNI), a majority-owned subsidiary of Viragen, Inc. (OTC Bulletin Board: VRAI), today announced that a one for forty (1:40) reverse stock split of its issued and outstanding common stock will become effective at the close of business today, September 4, 2007.

The reverse stock split was first announced on June 29, 2007. The action was approved by Viragen International's Board of Directors and the holder of a majority of its outstanding voting securities as described in its definitive Information Statement on Schedule 14C filed with the Securities and Exchange Commission on August 12, 2007.

Effective with the reverse stock split, the trading symbol on the OTC Bulletin Board for Viragen International's common stock will change to "VRGE", and the new CUSIP number for its common stock will be 927637306. Any fractional shares which might result from the reverse split will be rounded up to the nearest whole share. The common stock will be quoted on the OTC Bulletin Board post-split at market open on Wednesday, September 5, 2007.

There will be a mandatory exchange of certificates following the effective time of the reverse stock split. Stockholders will not be charged for the issuance of a new stock certificate reflecting the post-split shares and new CUSIP number.

As soon as practicable, Viragen International will send a letter of transmittal to each holder of record of pre-split shares outstanding on the effective time of the reverse stock split which will contain instructions for the surrender of certificates representing the pre-split shares. Upon proper completion and execution of the letter of transmittal and return thereof, together with certificates representing pre-split shares, a stockholder will be entitled to receive a new certificate representing the number of post-split shares resulting from the reverse stock split. Stockholders should not submit any certificates until requested to do so in the letter of transmittal. No new certificate will be issued to a stockholder until such stockholder has surrendered his or her outstanding certificates together with the properly completed and executed letter of transmittal.

Beginning on September 5, 2007, each outstanding certificate representing pre-split shares will be deemed for all corporate purposes after the effective time of the reverse stock split to evidence ownership of the appropriate number of post-split shares. Holders of shares in street name need take no action, as their brokerage firm will take all necessary action relating to the reverse split.

About Viragen International, Inc.:

With international operations in the U.S., Scotland and Sweden, we are a bio-pharmaceutical company engaged in the research, development, manufacture, and commercialization of Multiferon(R) (multi-subtype, human alpha interferon), which is uniquely positioned in valuable niche indications, such as high-risk malignant melanoma, other niche cancer indications and selected infectious diseases.

We are a majority-owned subsidiary of Viragen, Inc. and operate through our foreign wholly-owned subsidiaries: ViraNative AB, a company located in Umea, Sweden; and Viragen (Scotland) Limited, a company located near Edinburgh, Scotland.

For more information, please visit:

Viragen, Inc. Corporate Contact:

Douglas Calder, Director of Communications

Phone: (954) 233-8746; Fax: (954) 233-1414


The foregoing press announcement contains forward-looking statements that can be identified by such terminology such as "believes," "expects," "potential," "plans," "suggests," "may," "should," "could," "intends," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the success of third- party marketing efforts; our ability to retain third-party distributors; our ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

SOURCE Viragen International, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Olympics of biotechnology has international flavor
2. Traffic data firm navigates international business
3. Catalyst International profit exceeds expectations
4. Lack of broadband hamstrings international videoconferencing
5. 30 days to success: Three simple steps to create your own international startup
6. TEKLYNX International announces new RFID software
7. Ruling enforces international trademark electronic filing requirements
8. Eleftheriou to lead Catalyst International
9. Internet trademark war goes international
10. International eyes drawn to Madisons games research
11. Plexus and SRI International team up to offer medical product development
Post Your Comments:
(Date:11/27/2015)... Nov. 27, 2015 /PRNewswire/--  Mallinckrodt plc (NYSE: ... that it has closed the sale of its global ... (GBT- NYSE Euronext) in a transaction valued at approximately ... facilities and a total of approximately 1,000 employees spread ... St. Louis area. This entire workforce ...
(Date:11/26/2015)... CHESHAM , England , November 26, ... Lightpoint Medical, an innovative medical device company specializing in ... Euro grant from the European Commission as part of the ... enabling the company to carry out a large-scale clinical trial ... -->      (Logo: , ...
(Date:11/25/2015)... 2015 Studies reveal the differences ... and pave the way for more effective treatment for one ...   --> --> ... problems in cats, yet relatively little was understood about the ... have been conducted by researchers from the WALTHAM Centre for ...
(Date:11/25/2015)... ... November 25, 2015 , ... A long-standing partnership between the ... has been formalized with the signing of a Memorandum of Understanding. , AMA ... Capt. Karl Minter and Capt. Albert Glenn Tuesday, November 24, 2015, at AMA ...
Breaking Biology Technology:
(Date:10/29/2015)... 29, 2015 Today, LifeBEAM , ... with 2XU, a global leader in technical performance ... hat with advanced bio-sensing technology. The hat will ... monitor key biometrics to improve overall training performance. ... two companies will bring together the most advanced technology, ...
(Date:10/26/2015)... India , October 26, 2015 ... --> adds ... 2015 to 2021 as well as ... 2015-2019 research reports to its collection ... . --> ...
(Date:10/23/2015)... , October 23, 2015 ... announce a mobile plug and play integration of physiological ... tasks SensoMotoric Instruments (SMI) present a ... solutions for eye tracking and physiological data registration. It ... SMI Eye Tracking Glasses 2w and physiological signals ...
Breaking Biology News(10 mins):